Skip to main content

Table 4 Hazard ratio's, 95 % confidence intervals and significance for progression-free survival and overall survival of advanced stage patients (significant factors are shown in bold)

From: Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer

 

Progression free survival

Overall survival

 

HR

95,0 % CI for HR

Sig.

HR

95,0 % CI for HR

Sig.

  

Lower

Upper

  

Lower

Upper

 

Age

1.019

0.986

1.053

0.266

1.028

1.003

1.054

0.03

Histology

   

0.641

   

0.003

Mucinous versus serous

1.134

0.498

2.583

0.765

1.223

0.605

2.471

0.575

Endometroid versus serous

0

0

.

0.983

21.448

3.539

130.006

0.001

Clear-cell versus serous

0.542

0.187

1.575

0.261

0.559

0.228

1.369

0.203

Adenocarcinoma unspecified versus serous

1.099

0.231

5.226

0.906

1.335

0.369

4.835

0.66

Differentiation

3.266

0.778

13.716

0.106

1.702

0.674

4.297

0.26

CA 125

        

<35

   

0.362

   

0.635

35–200

0.57

0.216

1.499

0.254

0.847

0.391

1.831

0.672

>200

0.62

0.254

1.515

0.295

0.709

0.34

1.478

0.359

Ascites

1.919

0.836

4.401

0.124

1.75

0.877

3.489

0.112

FIGO

        

IIB

   

0.076

   

0.044

III

0.311

0.077

1.26

0.102

0.294

0.101

0.854

0.024

IV

1.06

0.371

3.028

0.914

0.839

0.389

1.807

0.653

Cytoreduction

1.882

0.939

3.774

0.075

1.696

0.935

3.076

0.082

MMP-14 Overall Score

1.538

0.777

3.043

0.216

0.945

0.551

1.624

0.839

MMP-14 stroma

1.421

0.99

2.039

0.057

0.695

0.371

1.299

0.254

MMP-2 Overall Score

22.901

0

#######*

0.668

0.879

0.395

1.953

0.751

MMP-2 stroma

1.214

0.807

1.828

0.352

1.15

0.832

1.59

0.399

  1. HR Hazard Ratio, CI Confidence Interval, Sig. Significance, MMP Matrix Metalloproteinase
  2. * = because of the low number of patients 95 % CI can not be calculated